The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia

References

• Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975–2010. Bethesda, MD: National Cancer Institute; 2013.
   Google Scholar
• Tadmor T, Polliack A. Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choices. Blood Rev. 2012;26:15–23.
   PubMed Web of Science ®Google Scholar
• Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German chronic lymphocytic leukemia study group trials. Haematologica. 2014;99:1095–1100.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink A, Busch B, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic L. Blood. 2014;124: Abstract 19.
   PubMed Web of Science ®Google Scholar
• Morrison VA. Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis. 2014;59:S360–S364.
   PubMed Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005;23:7024–7031.
   PubMed Web of Science ®Google Scholar
• Lepretre S, Aurran T, Mahé B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012;119:5104–5110.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885–891.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Clin Oncol. 2007;25:793–798.
   PubMed Web of Science ®Google Scholar
• Geisler CH, van T, Veer MB, et al. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood. 2014;123:3255–3262.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997.
   PubMed Web of Science ®Google Scholar
• Hallek M, Tefferi A. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:447–460.
   Web of Science ®Google Scholar
• Fischer K, Bahlo J, Fink A, et al. Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–216.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–2437.
   PubMed Web of Science ®Google Scholar
• Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128:260–270.
   PubMed Web of Science ®Google Scholar
• Plackett TP, Boehmer ED, Faunce DE. Aging and innate immune cells. J Leukoc Biol. 2004;76:291–299.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2016;125:2497–2507.
   Web of Science ®Google Scholar
• Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007;109:2291–2298.
   PubMed Web of Science ®Google Scholar
• Eketorp Sylvan S, Lundin J, Ipek M, et al. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients. Ann Hematol. 2014;93:1725–1733.
   PubMed Web of Science ®Google Scholar
• Extermann M, Overcash J, Lyman G, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1988;16:1582–1587.
   Google Scholar
• Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Res. 1992;41:237–248.
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–1251.
   PubMed Web of Science ®Google Scholar
• Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142–148.
   PubMed Web of Science ®Google Scholar
• Kalbe E, Kessler J, Calabrese P, et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry. 2004;19:136–143.
   PubMed Web of Science ®Google Scholar
• Goede V, Bahlo J, Chataline V, et al. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group. Leuk Lymphoma. 2016;57:789–796.
   PubMed Web of Science ®Google Scholar
• Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49–62.
   PubMed Web of Science ®Google Scholar
• Molica S, Giannarelli D, Mirabelli R, et al. Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson cancer center model. Eur J Haematol. 2016;96:72–77.
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood. 2004;104:655–658.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, O’Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003;98:773–778.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki a. B, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Basquiera AL. Coronary ischemia related to alemtuzumab therapy. Ann Oncol. 2004;15:539–540.
   PubMed Web of Science ®Google Scholar
• Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12:178–180.
   PubMed Web of Science ®Google Scholar
• Hasib L, Lundberg AK, Zachrisson H, et al. Functional and homeostatic defects of regulatory T cells in patients with coronary artery disease. J Intern Med. 2015;279:63–77.
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4 + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106:2018–2025.
   PubMed Web of Science ®Google Scholar
• Lutsiak MEC, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–2868.
   PubMed Web of Science ®Google Scholar
• Havari E, Turner MJ, Campos-Rivera J, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology. 2014;141:123–131.
   PubMed Web of Science ®Google Scholar
• Dons EM, Raimondi G, Zhang H, et al. Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity. Am J Transplant. 2013;13:2169–2178.
   PubMed Web of Science ®Google Scholar
• Lee F, Luevano M, Veys P, et al. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface. PLoS One. 2014;9:e103254.
   Google Scholar